RBA-1 Inhibitors
RBA-1 inhibitors are molecules designed to suppress or block the activity of the RBA-1 protein, a TIR-only domain protein. These inhibitors function by interacting with the conserved Toll/interleukin-1 receptor (TIR) domain, preventing RBA-1 from engaging in its usual protein-protein interactions and downstream signaling. By binding to the TIR domain, RBA-1 inhibitors effectively disrupt its structural integrity or block its active sites, limiting its ability to participate in cellular processes that involve TIR domain-mediated signaling. Since RBA-1 consists solely of the TIR domain, inhibitors target this single functional region, providing specificity in modulating its unique role in signaling cascades. The molecular mechanisms by which these inhibitors act can include competitive binding, allosteric inhibition, or steric hindrance, each altering the natural behavior of the RBA-1 protein.
The structure of RBA-1 inhibitors often includes small molecules or peptides that can precisely interact with critical residues in the TIR domain, destabilizing or preventing the active form of the protein. Some inhibitors may bind tightly to prevent RBA-1 from adopting the conformations necessary for interaction with other proteins, while others may interfere with its recruitment into signaling complexes. The binding affinity and specificity of these inhibitors are critical for their effectiveness, allowing selective inhibition of RBA-1 over other TIR domain-containing proteins. Research into the design and function of RBA-1 inhibitors offers insight into the broader regulation of TIR domain proteins and contributes to a deeper understanding of the signaling mechanisms that these domains control. The study of RBA-1 inhibitors helps highlight the specific chemical interactions and structural features essential to inhibiting TIR domain activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks), which indirectly leads to the inhibition of RBA-1 by preventing the activation of downstream signaling pathways that are crucial for the protein's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK) signaling. Inhibiting MEK prevents the activation of ERK, which may be necessary for RBA-1's activity or stability. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, another kinase that can regulate the activity of various proteins, potentially including RBA-1, through phosphorylation. Inhibition of p38 MAPK can thus inhibit RBA-1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the regulation of a wide range of cellular processes. Inhibition of JNK signaling may impede pathways that facilitate the function of RBA-1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002, which by blocking PI3K activity, may reduce the activation of pathways necessary for RBA-1's function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK like PD98059, and thus it also prevents the activation of ERK signaling. ERK is often involved in the regulation of proteins, and its inhibition could lead to reduced RBA-1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mammalian target of rapamycin (mTOR), a key signaling molecule that may interact with RBA-1-related pathways. Inhibition of mTOR signaling can lead to reduced protein synthesis and function, which may include RBA-1 inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases can affect numerous signaling pathways, potentially including those involving RBA-1. By inhibiting Src kinases, PP2 may inhibit RBA-1's function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor and may inhibit a range of kinases that affect RBA-1's activity or phosphorylation state, thereby inhibiting RBA-1. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of Rho-associated protein kinase (ROCK), which can regulate the actin cytoskeleton and is possibly linked to signaling pathways that involve RBA-1. Inhibition of ROCK may lead to inhibition of RBA-1 activity. | ||||||